Comtan

Comtan is a brand name of entacapone, approved by the FDA in the following formulation(s):

COMTAN (entacapone - tablet; oral)

• 
  Manufacturer: ORION
  
  Approval date: October 19, 1999
  
  Strength(s): 200MG ^[RLD]

Has a generic version of Comtan been approved?

No. There is currently no therapeutically equivalent version of Comtan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Comtan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmacologically active catechol derivatives
  Patent 5,446,194
  Issued: August 29, 1995
  Inventor(s): Backstrom; Reijo J. & Heinola; Kalevi E. & Honkanen; Erkki J. & Kaakkola; Seppo K. & Kairisalo; Pekka J. & Linden; Inge-Britt Y. & Mannisto; Pekka I. & Nissinen; Erkki A. O. & Pohto; Pentti & Pippuri; Aino K. & Pystynen; Jarmo J.
  Assignee(s): Orion-yhtyma Oy
  A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.
  
  Patent expiration dates:
  
  
  • October 19, 2013
    
    ✓ 
    Drug substance
  
  



• 
  Oral compacted composition comprising catechol derivatives
  Patent 6,599,530
  Issued: July 29, 2003
  Inventor(s): Kari; Vahervuo
  Assignee(s): Orion Corporation
  The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and croscarmellose sodium. The composition is premised on the discovery that croscarmellose sodium increases the release rate of entacapone or nitecapone from an oral compacted composition. Preferably the amount of croscarmellose sodium in the composition is at least 6% by weight, preferably from about 8% to about 16% by weight, especially from about 10% to about 14% by weight.
  
  Patent expiration dates:
  
  
  • September 14, 2018
    
    ✓ 
    Patent use: TREATMENT OF PARKINSON'S DISEASE
    ✓ 
    Drug product
  
  

See also...

• Comtan Consumer Information (Wolters Kluwer)
• Comtan Consumer Information (Cerner Multum)
• Comtan Advanced Consumer Information (Micromedex)
• Comtan AHFS DI Monographs (ASHP)
• Entacapone Consumer Information (Wolters Kluwer)
• Entacapone Consumer Information (Cerner Multum)
• Entacapone Advanced Consumer Information (Micromedex)
• Entacapone AHFS DI Monographs (ASHP)